Skip to content

TREVI THERAPEUTICS, INC.

TRVI

CIK 0001563880

← back to feed
Revenue (TTM)
—
Q1 Apr 2026
Net Income (TTM)
−$47.64M
+10.8% YoY Q1 Apr 2026
EPS Diluted (TTM)
−$0.35
+31.9% YoY Q1 Apr 2026
Gross Margin
—
Q1 Apr 2026
Operating Margin
—
Q1 Apr 2026
Net Margin
—
Q1 Apr 2026
Free Cash Flow (TTM)
−$49.06M
Q1 Apr 2026
Cash
$19.41M
Q1 Apr 2026
Total Debt
—
Q1 Apr 2026
Shares Outstanding
141.98M sh
Q1 Apr 2026

Revenue & Net Income

EPS (Diluted)

Cash Flow

Revenue Growth (YoY)

No data available for this metric.

Balance Sheet

Cash vs Debt

Recent filings